-
81
-
82
Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
83
Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
84
Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
85
Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
86
Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Can...
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
87
Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Can...
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
88
Supplementary Data 3 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
89
Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
90
Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
91
Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
92
Supplementary Data 4 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
93
Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
94
Supplementary Data 1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
95
CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
96
Supplementary Data 5 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
97
Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
98
Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
99
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”
-
100
Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Izdano 2025Teme: “…Cancer Detection and Diagnosis…”